Decramer A.,AZ Delta Roeselare Menen |
Leclercq C.,Institute Of La Main
Techniques in Hand and Upper Extremity Surgery | Year: 2015
We report the case of a 47-year-old man who presented with a pathologic fracture of the middle phalanx of the fourth finger. The treatment of this juxta-articular lesion close to the proximal interphalangeal joint was performed in 2 stages. First, a biopsy was carried out combined with fixation of the fracture by a Suzuki dynamic external fixator. After 6 weeks, a curettage of the confirmed enchondroma was performed with iliac crest grafting, leaving the external fixator for another 4 weeks. With a follow-up of 48 months, a satisfying functional result has been obtained with a remarkable remodeling of the painless proximal interphalangeal joint. Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
The Belgian trial with azithromycin for acute COPD exacerbations requiring hospitalization: An investigator-initiated study protocol for a multicenter, randomized, double-blind, placebo-controlled trial
Vermeersch K.,Catholic University of Leuven |
Gabrovska M.,Center Hospitalier University Saint Pierre |
Deslypere G.,Jessa Ziekenhuis |
Demedts I.K.,AZ Delta Roeselare Menen |
And 9 more authors.
International Journal of COPD | Year: 2016
Background: Long-term use of macrolide antibiotics is effective to prevent exacerbations in chronic obstructive pulmonary disease (COPD). As risks and side effects of long-term intervention outweigh the benefits in the general COPD population, the optimal dose, duration of treatment, and target population are yet to be defined. Hospitalization for an acute exacerbation (AE) of COPD may offer a targeted risk group and an obvious risk period for studying macrolide interventions. Methods/design: Patients with COPD, hospitalized for an AE, who have a smoking history of ≥10 pack-years and had ≥1 exacerbation in the previous year will be enrolled in a multicenter, randomized, double-blind, placebo-controlled trial (NCT02135354). On top of a standardized treatment of systemic corticosteroids and antibiotics, subjects will be randomized to receive either azithromycin or placebo during 3 months, at an uploading dose of 500 mg once a day for 3 days, followed by a maintenance dose of 250 mg once every 2 days. The primary endpoint is the time-to-treatment failure during the treatment phase (ie, from the moment of randomization until the end of intervention). Treatment failure is a novel composite endpoint defined as either death, the admission to intensive care or the requirement of additional systemic steroids or new antibiotics for respiratory reasons, or the diagnosis of a new AE after discharge. Discussion: We investigate whether azithromycin initiated at the onset of a severe exacerbation, with a limited duration and at a low dose, might be effective and safe in the highest risk period during and immediately after the acute event. If proven effective and safe, this targeted approach may improve the treatment of severe AEs and redirect the preventive use of azithromycin in COPD to a temporary intervention in the subgroup with the highest unmet needs. © 2016 Vermeersch et al.
Joye I.,Catholic University of Leuven |
Joye I.,University Hospitals Leuven |
Macq G.,Belgian Cancer Registry |
Vaes E.,Belgian Cancer Registry |
And 18 more authors.
Radiotherapy and Oncology | Year: 2016
In a previous national central review project, 74% of the rectal cancer clinical target volumes (CTVs) needed a modification. In a follow-up initiative, we evaluated whether the use of refined international consensus guidelines improves the uniformity of CTV delineation in clinical practice. © 2016 Elsevier Ireland Ltd.
Oyaert M.,AZ Delta Roeselare Menen |
Demedts I.,Center for Thoracic Oncology |
Boone E.,AZ Delta Roeselare Menen |
Dedeurwaerdere F.,AZ Delta Roeselare Menen |
And 3 more authors.
Molecular Diagnosis and Therapy | Year: 2015
Introduction: Mutations in the epidermal growth factor receptor (EGFR) have been reported as predictive markers of tumour response to tyrosine kinase inhibitors (TKIs) in patients with non-small cell lung cancer (NSCLC). Although the “common” EGFR mutations have been associated with response to EGFR-TKIs, the correlation with response to treatment for many other rare mutations is still unclear. The aim of this study was to investigate the clinical significance of rare and complex mutations, and the efficacy of EGFR-TKIs in this selected group of patients. Methods: Three hundred and thirty patients with stage IIIB/IV NSCLC (106 females aged 62.5 ± 1.1 years; 224 males aged 68.0 ± 0.6 years) were enrolled in the study. Formalin fixed paraffin embedded tissue samples were screened for mutations using a high resolution melting technique, followed by Sanger sequencing of exons 18-21 of the EGFR-gene. Mutation status was also tested using the Roche Cobas®EGFR mutation test. Results: EGFR mutations were detected in 31 tumours (9.4 %). Eleven cases carried novel mutations, six of these patients were treated with erlotinib or gefitinib. A response rate (RR) of 50.0 % was obtained in the group with rare EGFR mutations, the PFS was 3.0 months [standard deviation (STD) = 5.4 months]. The RR to EGFR-TKIs in patients with conventional EGFR mutations was 85 % with a median PFS of 10.5 months (STD = 3.6 months). Conclusion: We reported six patients with rare EGFR mutations of unknown clinical significance and their association with EGFR-TKIs. Report of cases harbouring rare mutations can support the decision making progress in this subset of patients. © 2015, Springer International Publishing Switzerland.